{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:22:54Z","timestamp":1788024174672,"version":"build-2784847793"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.msard.2018.11.029","type":"journal-article","created":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T00:06:27Z","timestamp":1543449987000},"page":"403-405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Acquired haemophilia A as a secondary autoimmune disease after alemtuzumab treatment in multiple sclerosis: A case report"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9409-6864","authenticated-orcid":false,"given":"M.","family":"Pisa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Della Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Coluccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5987-5739","authenticated-orcid":false,"given":"V.","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"D'Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Moiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Jul (7)","key":"10.1016\/j.msard.2018.11.029_bib0003","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/jnnp-2013-307042","article-title":"Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis","volume":"85","author":"Azzopardi","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"Aug 1 (8)","key":"10.1016\/j.msard.2018.11.029_bib0001","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","article-title":"Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab","volume":"74","author":"Baker","year":"2017","journal-title":"JAMA Neurol."},{"issue":"Dec (5)","key":"10.1016\/j.msard.2018.11.029_bib0005","article-title":"Acquired haemophilia A complicating alemtuzumab therapy for multiple sclerosis","volume":"2017","author":"McCaughan","year":"2017","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.msard.2018.11.029_bib0004","series-title":"Proceedings of the 3rdCongress of the European Academy of Neurology","article-title":"First reported case of aquired Hemophilia A (AHA) as secondary autoimmune disease following alemtuzumab treatment in multiple sclerosis","author":"Pisa","year":"2017"},{"key":"10.1016\/j.msard.2018.11.029_bib0002","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/1352458515614092","article-title":"Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort","volume":"22","author":"Willis","year":"2016","journal-title":"Mult. Scler."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818305212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818305212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:45:33Z","timestamp":1761900333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818305212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":5,"alternative-id":["S2211034818305212"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.11.029","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acquired haemophilia A as a secondary autoimmune disease after alemtuzumab treatment in multiple sclerosis: A case report","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.11.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}